DevPro Biopharma
Company
DevPro Biopharma develops one asset, in phase 2 (AP01 in hypersensitivity pneumonitis). Mostly small molecule acting on inflammation.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 1
- Signal
Pipeline
1Inhaled formulation of pirfenidone targeting fibrosis pathway.
Phase 2, Small molecule, Inflammation, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals9
- Similar companies6